Direct Acting Antivirals vs Comparison: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.00496 | 0.00397 | 0.00619 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.12 | 0.115 | 0.124 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.115 | -0.119 | -0.11 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.0415 | 0.0331 | 0.052 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.0367 | 0.0292 | 0.0461 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer death from any cause on Direct Acting Antivirals than on Comparison | 8.73 | 8.37 | 9.11 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Direct Acting Antivirals | Patients who receive a direct acting antiviral enter the DAA cohort at the time of initiation of the drug.~Direct Acting Antivirals: The time period during which a patient is dispensed the medication and for up to 180 days after initiation of the medication. | 77 | 15,524 | EG000 | ClinicalTrials.gov |
| Group 2 | Comparison | The exposure time of patients who have not received a direct acting antiviral (patients can change from the comparison to the DAA group once they receive the medication) | 2,186 | 18,284 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, all-cause mortality | ClinicalTrials.gov |
| Time frame | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C | ClinicalTrials.gov |
| NCT number | NCT03423641 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Hepatitis C, Chronic | ClinicalTrials.gov |
| Interventions | Direct Acting Antivirals | ClinicalTrials.gov |
| Lead sponsor | Kaiser Permanente | ClinicalTrials.gov |
| Results first posted | 2019-08-07 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT03423641?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.